枸橼酸托法替布(Tofacitinib Citrate) - 药物靶点：JAK1 x JAK2 x JAK3_在研适应症：强直性脊柱炎，银屑病关节炎，溃疡性结肠炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Tasocitinib、Tasocitinib citrate、TOFACITINIB

+ [23]

靶点

JAK1 x JAK2 x JAK3

作用机制

JAK1抑制剂(酪氨酸蛋白激酶JAK1抑制剂)、JAK2抑制剂(酪氨酸蛋白激酶JAK2抑制剂)、JAK3抑制剂(酪氨酸蛋白激酶JAK3抑制剂)

治疗领域

免疫系统疾病感染消化系统疾病+ [6]

在研适应症

强直性脊柱炎银屑病关节炎溃疡性结肠炎+ [16]

非在研适应症

同种异体移植排斥反应新型冠状病毒感染克罗恩病+ [12]

原研机构

Pfizer Inc.

在研机构

晖致制药（大连）有限公司

Pfizer Inc.Pfizer Europe MA EEIG

+ [12]

非在研机构

Pfizer Manufacturing Deutschland GmbH

最高研发阶段批准上市

首次获批日期

美国 (2012-11-06),

类风湿关节炎

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)、特殊审批 (中国)

登录后查看时间轴

结构

分子式C22H28N6O8

InChIKeySYIKUFDOYJFGBQ-YLAFAASESA-N

CAS号540737-29-9

关联

433

项与枸橼酸托法替布相关的临床试验

NCT06654882 / Not yet recruiting临床3期IIT

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis

This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).

开始日期2025-02-01

申办/合作机构

Duke University

[+1]

NCT06465732 / Not yet recruiting临床4期IIT

A Randomized Controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Combination With Short-term Low-dose Tofacitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by intense pruritus and sleep disturbances. The clinical manifestations of AD are varied, with the most basic features being dry skin, chronic eczema-like dermatitis, and intense pruritus. The prevalence in children and adults is about 30% and 10%, respectively. Most patients respond well to topical anti-inflammatory drugs, but approximately 10 percent of patients with moderate-to-severe AD require one or more systemic therapies to achieve good disease control. Although nonspecific immunosuppressive drugs (including glucocorticoids, cyclosporine A, methotrexate, azathioprine, or mycophenolate mofetil) are effective in alleviating or controlling these disorders to some extent, their overall efficacy in patients is limited and associated with significant side effects with long-term use.
The main hallmarks of systemic type II inflammation are eosinophilia and elevated serum immunoglobulin E (IgE) levels. Type II inflammatory response is not only associated with allergic reactions, but is also a driver of such diseases. The release of cytokines (interleukins 4, 5, and 13) in the response to type II inflammation can trigger a lymphocyte-mediated type II inflammatory response, inducing the onset and progression of allergic diseases. Reducing the inflammatory response by inhibiting the above-mentioned inflammatory factors is a potential therapeutic means for the treatment of allergic diseases represented by AD.
Investigational drug Dupilumab injection, an interleukin-4 receptor α (IL-4Rα) antagonist, is a human monoclonal antibody that binds IL-4Rα and inhibits IL-4 and IL-13 signaling. With a molecular weight of about 147 kDa, it inhibits the signaling of interleukin 4 and interleukin 13 and blocks its signaling pathway through the atopic binding of the interleukin 4Ra subunit shared with the interleukin 4 and interleukin 13 receptor complex, and blocks their signaling pathways, which can achieve continuous, efficient and safe improvement of skin lesions, itching and other symptoms and alleviate the condition.
Tofacitinib is a Janus kinase (JAK) inhibitor. JAK is an intracellular enzyme that conducts signals generated by cytokine or growth factor-receptor interactions on cell membranes, thereby affecting cell hematopoiesis and cellular immune function.

开始日期2025-01-01

申办/合作机构

Second Affiliated Hospital Zhejiang University College of

IRCT20240920063104N1 / SuspendedN/AIIT

A comparative clinical trial study of the therapeutic effects and side effects of the two drugs Baricitinib and Tofacitinib in pediatric patients with Alopecia Areata

开始日期2024-12-21

申办/合作机构

Tehran University of Medical Sciences

100 项与枸橼酸托法替布相关的临床结果

登录后查看更多信息

100 项与枸橼酸托法替布相关的转化医学

登录后查看更多信息

100 项与枸橼酸托法替布相关的专利（医药）

登录后查看更多信息

3,158

项与枸橼酸托法替布相关的文献（医药）

2024-12-31·Journal of medical economics

Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia

Article

作者: Al-Homood, Ibrahim ; Alsaqa'aby, Mai ; Sharma, Yuvraj ; Hamad, Tharwat M ; Alzahrani, Zeyad ; Anwar, Ali ; Husain, Waleed ; Mohamed, Omneya ; Al-Abdulkarim, Hana ; Al Omari, Bedor ; Jaheen, Ahmed M ; Attar, Suzan M

AIM:

To evaluate cost-effectiveness of upadacitinib (targeted synthetic-disease modifying anti-rheumatic drug [ts-DMARD]) as first-line (1 L) treatment versus current treatment among patients with rheumatoid arthritis (RA) in the Kingdom of Saudi Arabia (KSA), who had an inadequate response to prior conventional-synthetic (csDMARDs) and/or biologic-DMARDs (bDMARDs).

METHODS:

This Excel-based model included patients with moderate (Disease Activity Score [DAS28]: >3.2 to ≤5.1) or severe RA (DAS28 > 5.1). Cost-effectiveness of current treatment (1 L: adalimumab-originator/biosimilar; second-line (2 L): other bDMARDs/tofacitinib) was compared against a new treatment involving two scenarios (1 L: upadacitinib, 2 L: adalimumab-biosimilar [scenario-1]/adalimumab-originator [scenario-2]) for a 10-year time-horizon from societal perspective. Model outcomes included direct and indirect costs, quality-adjusted life-years (QALYs), hospitalization days, number of orthopedic surgeries, and incremental cost-utility ratio (ICUR) per QALY.

RESULTS:

With the current pathway, estimated total societal costs for 100 RA patients over 10-year period were Saudi Riyal (SAR) 50,450,354 (United States dollars [USD] 13,453,428) (moderate RA) and SAR50,013,945 (USD13,337,052) (severe RA). New pathway (scenario-1) showed that in patients with moderate-to-severe RA, upadacitinib led to higher QALY gain (+8.99 and +15.63) at lower societal cost (cost difference: -SAR2,023,522 [-USD539,606] and -SAR3,373,029 [-USD899,474], respectively). Thus, as 1 L, upadacitinib projects "dominant" ICUR per QALY over current pathway. Moreover, in alternate pathway (scenario-2), upadacitinib also projects "dominant" ICUR per QALY for patient with severe RA (QALY gain: +15.63; cost difference: -SAR 164,536 [-USD43,876]). However, moderate RA was associated with additional cost of SAR1,255,696 (USD334,852) for improved QALY (+8.99) over current pathway (ICUR per QALY: SAR139,742 [USD37,264]). Both scenarios resulted in reduced hospitalization days (scenario-1: -14.83 days; scenario-2: -11.41 days) and number of orthopedic surgeries (scenario-1: -8.36; scenario-2: -6.54) for moderate-to-severe RA over the current treatment pathway.

CONCLUSION:

Upadacitinib as 1 L treatment in moderate-to-severe RA can considerably reduce healthcare resource burden in KSA, majorly due to reduced drug administration/monitoring/hospitalization/surgical and indirect costs.

2024-12-31·ANNALS OF MEDICINE

Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study

Article

作者: Goren, Idan ; Ollech, Jacob E ; Yanai, Henit ; Avni-Biron, Irit ; Friedenberg, Adi ; Dotan, Iris ; Broitman, Yelena ; Sharar Fischler, Tali ; Eran-Banai, Hagar ; Pauker, Maor H ; Snir, Yifat ; Cohen, Shaked

INTRODUCTION:

Real-world data on tofacitinib's effectiveness is limited and mainly retrospective or registry-based. We elected to conduct a pragmatic prospective study to assess the efficacy of tofacitinib for moderate to severe ulcerative colitis (UC), aiming to evaluate the ability of intestinal ultrasound (IUS) to discriminate responders vs. non-responders in real-time.

METHODS:

This pragmatic prospective clinical study included consecutive adult patients starting tofacitinib treatment for active moderate to severe UC. Patients were evaluated at baseline and after 8 weeks of tofacitinib (clinical, biomarker, endoscopy, and IUS). The primary outcome was clinical response defined by a decrease in the full Mayo score (fMS) of ≥3 at week 8. Next, we explored ultrasonographic parameters in the sigmoid colon as potential real-time classifiers to differentiate between responders and non-responders at week 8.

RESULTS:

Overall, 30 adult patients started tofacitinib; the median age was 26.3 years (IQR 22.5-39.8), and 50% were female. Most patients (86.6%) had left-sided or extensive colitis, 96.7% had previously failed biologic therapy, and 60% (18/30) were on oral corticosteroids at the start of tofacitinib. At week 8, clinical response (a decrease in the fMS ≥ 3) and remission (fMS ≤ 2) rates were 40% (12/30) and 20% (6/30), respectively. Biomarker response (FC < 250µg/g) and biomarker normalization (FC ≤ 100µg/g) were achieved in 47.6% (10/21) and 38.1% (8/21) of patients, respectively. Endoscopic healing (endoscopic Mayo sub-score [EMS] ≤ 1) was achieved in 33.3% (10/30) of patients. Sigmoid bowel wall normalization as assessed by IUS (sBWT ≤ 3) was achieved in 18.2% (4/22). The best sBWT cut-off at week 8 to accurately classify endoscopic healing vs. no healing was a sBWT of 3.6 mm (AUC of 0.952 [95% CI: 0.868-1.036], p < 0.001).

CONCLUSION:

In this real-world pragmatic prospective study, tofacitinib was an effective treatment for moderate to severe UC, and IUS at week 8 accurately discriminated treatment response from non-response.

2024-12-31·The Journal of dermatological treatment

A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor

Article

作者: Zheng, Chunzhi ; Liu, Hong ; Zhou, Guizhi ; Yu, Yueqian

AIM:

This case study aims to report the efficacy and safety of a Janus kinase (JAK) inhibitor in the treatment of generalized eosinophilic pustular folliculitis (EPF).

METHODS:

We present a case of a 16-year-old Chinese patient who had been suffering from EPF for two years and had shown no response to both topical and systemic glucocorticoids. The patient was subsequently treated with oral tofacitinib at a dosage of 5mg daily.

RESULTS:

Significant remission of eruption and pruritus was observed in the patient upon treatment with tofacitinib. However, a relapse occurred upon dose reduction. Subsequent switch to the highly selective JAK1 inhibitor upadacitinib resulted in complete recovery, with the patient achieving a symptom-free status after six months.

CONCLUSIONS:

JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.

549

项与枸橼酸托法替布相关的新闻（医药）

2024-11-04

·米内网

科伦大爆发！拿下21个重磅品种，162个过评品种霸屏，21个品种备战第十批集采

精彩内容第十批集采报量目录官宣，科伦药业21个过评品种在列。今年以来，科伦药业研发管线快速推进，21个品种（3个首仿）获批上市、9个存量品种过评。前三季度公司研发费用15.84亿元，39款新药处于申报临床及以上阶段，5款上市可期。公司累计有162个品种过评（49个首家），21个品种拟纳入第十批集采。 Q3净利润增长19.88%，1类新药上市在即 10月28日，科伦药业发布2024年三季度报告，公司第三季度的营业收入49.62亿元，同比增长0.35%；归母净利润6.71亿元，同比增长19.88%；扣非净利润6.93亿元，同比增长21.49%。得益于销售收入的增加及成本控制的有效性，今年前三季度科伦药业的营业收入达到了167.89亿元，同比增长6.64%；归母净利润24.71亿元，增幅为25.85%；扣非净利润24.47亿元，同比增长27.32%。科伦药业三季报主要财务数据科伦药业坚持研发投入，2024年前三季度研发费用15.84亿元。2024年至今，公司已有7款1类新药的IND申请获CDE承办，其中3款1类新药注射用SKB571、注射用SKB500、注射用MK-6204为首次申报IND。此外，1类新药塔戈利单抗注射液、2类改良型新药布瑞哌唑口溶膜提交上市申请。 10月31日，科伦药业公告称，控股子公司科伦博泰的核心产品芦康沙妥珠单抗（sac-TMT）新药申请已获国家药监局（NMPA）受理。该药物用于治疗经表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗后进展的EGFR突变局部晚期或转移性非小细胞肺癌（NSCLC）成人患者。这是芦康沙妥珠单抗获NMPA受理的第三个上市申请。目前，科伦药业主要有39款新药处于申报临床及以上研究阶段，涉及24款1类新药、13款2类改良型新药、2款生物类似药。其中，3款1类新药芦康沙妥珠单抗（TROP2 ADC）、A166（HER2 ADC）、A167（PD-L1），生物类似药西妥昔单抗，改良型新药布瑞哌唑口溶膜预计2024-2025年陆续获批上市，公司的创新板块即将商业化兑现。拿下21个品种，162个过评品种亮眼今年以来，科伦药业仿制药管线持续推进，新注册分类品种获批上市、存量品种通过一致性评价消息不断。 2024年至今科伦药业获批产品新注册分类品种审评方面，科伦药业有21个品种获批上市并视同过评，包括吡拉西坦注射液、奥拉帕利片、艾曲泊帕乙醇胺片、瑞戈非尼片、艾地骨化醇软胶囊、盐酸乌拉地尔注射液、间苯三酚注射液等，进一步丰富了公司的产品布局。 21个品种中，多个品种为国内首批上市，注射用美罗培南/氯化钠注射液、ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（16%）注射液、艾曲泊帕乙醇胺片为国内首仿+首家过评，布比卡因脂质体注射液、奥拉帕利片为国产第2家，地屈孕酮片、麦考酚钠肠溶片为国产第3家。存量品种一致性评价方面，科伦药业的注射用头孢唑林钠、注射用哌拉西林钠、甘油果糖氯化钠注射液、乳酸钠林格注射液、复方醋酸钠林格注射液、注射用头孢噻肟钠、腹膜透析液(乳酸盐-G1.5%)、腹膜透析液(乳酸盐-G2.5%)、腹膜透析液(乳酸盐-G4.25%)相继过评。截至目前，科伦药业已有162个品种通过/视同通过一致性评价。其中，49个品种为国内首家过评，氢溴酸西酞普兰胶囊、琥珀酸曲格列汀片、阿奇霉素分散片、氢溴酸替格列汀片、泊沙康唑口服混悬液、注射用美罗培南/氯化钠注射液等17个品种为独家过评。科伦药业年度过评品种情况从治疗领域上看，162个品种主要集中在全身用抗感染药物（51个）、血液和造血系统药物（38个）、抗肿瘤和免疫调节剂（16个）、消化系统及代谢药（16个）。米内网数据显示，这四大治疗领域2023年在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额均超过1000亿元。抢攻168亿市场，21个品种备战第十批集采已落地执行的八批化药集采中，科伦药业分别有1个、5个、4个、4个、11个、11个、7个、4个品种成功中选，合计47个品种。集采常态化推进背景下，科伦药业恰逢产品线密集收获期，并积极参与集采，已跻身集采头部供应商之列。 11月1日，国家组织药品联合采购办公室发布通知，开展第十批国家组织药品集中采购相关药品信息填报工作，62个品种（263个品规）被纳入填报范围。科伦药业有21个过评品种在列，是本次集采的主力军。科伦药业第十批拟集采品种竞争格局 21个通用名药品2023年在中国公立医疗机构终端合计销售额超过168亿元，其中哌拉西林注射剂、西格列汀口服常释剂型、间苯三酚注射剂、氨苄西林注射剂、利格列汀口服常释剂型、复方聚乙二醇电解质散、己酮可可碱注射剂等7个药品销售额均超过10亿元。从竞争格局上看，15个药品过评企业达10家及以上，其中间苯三酚注射剂、西格列汀口服常释剂型过评企业均有34家，己酮可可碱注射剂、舒更葡糖钠注射液分别有22家、21家企业过评，竞争十分激烈。而枸橼酸托法替布缓释片、泊沙康唑肠溶片分别有6家、7家企业过评，竞争相对较小。从市场份额上看，科伦药业具备参标资格的21个品种的市场份额普通较低，若中标可进一步为公司仿制药业务贡献增量。11个品种市场份额为零，其中7个为2023年或2024年新获批上市的品种，包括间苯三酚注射液、己酮可可碱注射液、艾地骨化醇软胶囊、瑞戈非尼片、泊沙康唑注射液、枸橼酸托法替布缓释片等，可借助集采中标快速抢占市场。资料来源：米内网数据库、公司公告注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

抗体药物偶联物财报生物类似药申请上市上市批准

2024-11-01

·米内网

【瞩目】大涨126%的明星药，葫芦娃药业抢国内首仿

精彩内容近日，海南葫芦娃药业集团提交了头孢托仑匹酯颗粒的4类仿制上市申请获得CDE承办，该产品是一款亿元级别的头孢类明星药，目前仅有原研企业获批进口。今年以来，葫芦娃药业已有11个新产品获批，目前报产在审的产品超过30个。图1：葫芦娃药业最新申报的产品来源：CDE官网明治的头孢托仑匹酯已在中国上市多年，涉及产品有头孢托仑匹酯颗粒和头孢托仑匹酯片，均未有国产仿制药获批，在中国三大终端六大市场（统计范围见文末），头孢托仑匹酯颗粒2023年的销售额突破1亿元，2024上半年增长率为126.41%。图2：头孢托仑匹酯颗粒的销售情况（单位：万元）来源：米内网格局数据库从渠道来看，公立医院终端（城市公立医院+县级公立医院）是主要销售阵地，占比保持在九成以上，近几年零售药店终端（城市实体药店+网上药店）以及公立基层医疗终端（城市社区中心+乡镇卫生院）的占比逐步提升，2024上半年均升至3%以上。针对头孢托仑匹酯颗粒，葫芦娃药业在今年7月提交的4类仿制上市申请（CYHS2402029）正在审评审批中，本次再有受理号报产，可见公司非常重视这个畅销产品。图3：今年以来葫芦娃药业获批的新产品来源：米内网中国上市药品（MID）数据库表1：葫芦娃药业目前报产在审的新品来源：米内网中国申报进度（MED）数据库 2024年葫芦娃药业收获满满，已获批新品11个，分布在7个亚类。目前公司报产在审的新品有1个中药新药和32个化药仿制药，共涉及10个大类（22个亚类），易黄颗粒是按古代经典名方目录管理的中药复方制剂，目前仅1家企业申报上市，葫芦娃药业有望拿下首家获批；枸橼酸托法替布口服溶液、维生素K滴剂、头孢托仑匹酯颗粒目前均未有国内药企获得生产批文，公司将参与国内首仿争夺，未来几年葫芦娃药业将进入新品获批爆发期，值得期待。资料来源：CDE官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至10月31日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

2024-10-30

·米内网

【火热】12亿注射剂！重庆药友获批了

精彩内容 10月29日，NMPA官网显示，重庆药友制药以仿制3类报产的注射用盐酸罗沙替丁醋酸酯获批上市，视同过评。该药是治疗与胃酸分泌相关疾病的药物，2023年在中国公立医疗机构终端销售额接近12亿元。盐酸罗沙替丁醋酸酯是一款组胺H2受体拮抗剂，可以有效抑制胃酸分泌，临床上用于上消化道出血（由消化性溃疡、急性应激性溃疡、出血性胃炎等引起）的低危患者。米内网数据显示，2023年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端注射用盐酸罗沙替丁醋酸酯销售额接近12亿元，2024年上半年其销售额超过7亿元。中国公立医疗机构终端注射用盐酸罗沙替丁醋酸酯销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局注射用盐酸罗沙替丁醋酸酯为第十批拟集采品种，目前已有扬子江药业、奥赛康、瑞阳制药、汇宇制药、双鹤药业、重庆药友制药、哈药生物等14家企业过评，市场竞争激烈。 2024年至今重庆药友获批上市品种来源：米内网中国申报进度（MED）数据库今年以来，重庆药友制药（不含子公司）已有12个品种获批上市并视同过评，包括注射用盐酸罗沙替丁醋酸酯、甲磺酸仑伐替尼胶囊、普伐他汀钠片、阿仑膦酸钠片、注射用尼可地尔、贝前列素钠片、间苯三酚注射液、阿立哌唑口崩片、盐酸舍曲林片、盐酸鲁拉西酮片、琥珀酸美托洛尔缓释片、枸橼酸托法替布片等。资料来源：米内网数据库、NMPA注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

上市批准

100 项与枸橼酸托法替布相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09783	枸橼酸托法替布	L04AA29	DB08895

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
强直性脊柱炎	欧盟	Pfizer Europe MA EEIG	2017-03-22
强直性脊柱炎	冰岛	Pfizer Europe MA EEIG	2017-03-22
强直性脊柱炎	列支敦士登	Pfizer Europe MA EEIG	2017-03-22
强直性脊柱炎	挪威	Pfizer Europe MA EEIG	2017-03-22
银屑病关节炎	欧盟	Pfizer Europe MA EEIG	2017-03-22
银屑病关节炎	冰岛	Pfizer Europe MA EEIG	2017-03-22
银屑病关节炎	列支敦士登	Pfizer Europe MA EEIG	2017-03-22
银屑病关节炎	挪威	Pfizer Europe MA EEIG	2017-03-22
溃疡性结肠炎	欧盟	Pfizer Europe MA EEIG	2017-03-22
溃疡性结肠炎	冰岛	Pfizer Europe MA EEIG	2017-03-22
溃疡性结肠炎	列支敦士登	Pfizer Europe MA EEIG	2017-03-22
溃疡性结肠炎	挪威	Pfizer Europe MA EEIG	2017-03-22
幼年特发性关节炎	欧盟	Pfizer Europe MA EEIG	2017-03-22
幼年特发性关节炎	冰岛	Pfizer Europe MA EEIG	2017-03-22
幼年特发性关节炎	列支敦士登	Pfizer Europe MA EEIG	2017-03-22
幼年特发性关节炎	挪威	Pfizer Europe MA EEIG	2017-03-22
少关节关节炎	欧盟	Pfizer Europe MA EEIG	2017-03-22
少关节关节炎	冰岛	Pfizer Europe MA EEIG	2017-03-22
少关节关节炎	列支敦士登	Pfizer Europe MA EEIG	2017-03-22
少关节关节炎	挪威	Pfizer Europe MA EEIG	2017-03-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斑块状银屑病	申请上市	中国	Pfizer Manufacturing Deutschland GmbH	2022-01-06
多形性胶质母细胞瘤	临床3期	美国	Pfizer Inc.	2022-10-07
新型冠状病毒感染	临床3期	巴西	Pfizer Inc.	2020-09-16
全身型幼年特发性关节炎	临床3期	美国	Pfizer Inc.	2018-05-10
全身型幼年特发性关节炎	临床3期	美国	晖致制药（大连）有限公司	2018-05-10
全身型幼年特发性关节炎	临床3期	美国	Pharmacia & Upjohn	2018-05-10
全身型幼年特发性关节炎	临床3期	中国	Pfizer Inc.	2018-05-10
全身型幼年特发性关节炎	临床3期	阿根廷	Pfizer Inc.	2018-05-10
全身型幼年特发性关节炎	临床3期	阿根廷	Pharmacia & Upjohn	2018-05-10
全身型幼年特发性关节炎	临床3期	阿根廷	晖致制药（大连）有限公司	2018-05-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03288324 (CTgov)	临床1/2期	皮肤红斑狼疮 \| 系统性红斑狼疮 \| 红斑狼疮	13	Tofacitinib (Cohort 1)	製鑰繭窪窪鏇糧網網鏇(簾範鹽繭觸積衊淵鹽餘) = 蓋餘積夢鹽鹹獵糧獵衊憲觸醖淵簾顧製廠窪獵 (積餘鏇鑰鹹餘簾鹹夢簾, 窪鹽繭窪憲窪壓醖鏇蓋 ~ 範壓繭蓋範鹽鏇餘醖遞) 更多	-	2024-07-30
				Tofacitinib (Cohort 1 & Cohort 2)	鹽齋襯範鏇糧醖鹹觸製(鑰鬱選壓鏇選壓糧選鹽) = 網繭餘憲繭齋鑰醖鏇齋築鬱膚鹽構構窪觸襯夢 (顧膚願製窪齋願襯艱襯, 選艱製糧廠鬱糧壓壓鑰 ~ 襯鏇壓淵憲襯淵醖鹽製) 更多
NCT01470612 \| NCT01458951 \| NCT01458574 \| NCT03281304 (global UC clinical program, Pubmed)	N/A	溃疡性结肠炎	1,157	Tofacitinib 5 mg b.i.d.	襯積壓廠觸遞淵鑰膚壓(膚鑰繭築夢獵願繭遞襯) = 糧範繭積範餘願鑰繭網蓋衊鹽鹹憲餘廠繭顧膚 (壓觸鏇壓齋網構願廠網 )	积极	2024-07-01
				Tofacitinib 10 mg b.i.d.	襯積壓廠觸遞淵鑰膚壓(膚鑰繭築夢獵願繭遞襯) = 顧艱窪襯窪觸廠範鹹鏇蓋衊鹽鹹憲餘廠繭顧膚 (壓觸鏇壓齋網構願廠網 )
NCT02092467 (ORAL Surveillance, Pubmed)	临床4期	类风湿关节炎 cardiovascular risk factor	4,362	Tofacitinib 5mg	製繭廠醖製憲構鹹簾餘(鹽淵鹹壓膚憲觸襯願憲) = 餘襯膚繭淵製鹹觸網蓋願選製鑰繭廠觸簾顧觸 (範憲鏇壓蓋壓蓋繭鬱繭 )	积极	2024-06-17
				Tofacitinib 10mg	製繭廠醖製憲構鹹簾餘(鹽淵鹹壓膚憲觸襯願憲) = 餘淵憲淵蓋醖夢襯艱衊願選製鑰繭廠觸簾顧觸 (範憲鏇壓蓋壓蓋繭鬱繭 )
NCT01500551 (NCT01500551, Pubmed)	临床2/3期	幼年特发性关节炎	225	Tofacitinib 5 mg	鏇醖窪鹹壓選願鏇蓋選(淵廠選艱積獵壓選積廠) = Of 225 patients with JIA (median (range) duration of treatment, 41.6 (1-103) months), 201 (89.3%) had AEs; 34 (15.1%) had serious AEs. 10 patients developed serious infections; three had herpes zoster. Two patients newly developed uveitis. 淵簾衊簾築衊繭願鹽觸 (觸繭網鏇範艱網艱築範 )	积极	2024-06-07
EULAR2024 人工标引	N/A	成人斯蒂尔病 pro-inflammatory cytokines \| JAK-STAT pathway	2	Tofacitinib	窪鏇醖鹽夢製顧遞鬱遞(艱齋夢淵築壓鏇醖獵膚) = 製鬱鬱壓齋餘構築糧獵製繭衊築鏇淵夢願鹹鬱 (衊鏇齋廠製窪遞襯觸簾 )	积极	2024-06-05
EULAR2024 人工标引	N/A	类风湿关节炎	7	Tofacitinib or Upadacitinib	齋壓獵觸糧蓋淵衊淵築(選簾製鹽鏇願網鏇鑰壓) = 壓鏇淵餘築衊壓獵憲醖醖蓋繭鹽膚繭壓鑰構憲 (憲獵襯衊獵願齋製鏇餘 ) 更多	积极	2024-06-05
ESCALATE-RA (EULAR2024) 人工标引	N/A	类风湿关节炎	1,378	Tofacitinib	願夢選鹹餘觸壓獵構獵(蓋窪製獵鹽鹽築網製壓) = 齋糧糧衊膚簾蓋築糧衊築鏇廠觸淵簾鑰願構構 (糧廠夢製夢淵窪醖艱願 ) 更多	积极	2024-06-05
EULAR2024 人工标引	N/A	类风湿关节炎	-	Tofacitinib	窪醖簾網鏇衊觸窪蓋窪(範鏇夢糧願餘獵繭淵獵) = 顧壓獵襯簾鏇觸夢鹹鑰網願鹹膚膚窪範膚窪襯 (築膚襯齋夢願壓壓餘艱 ) 更多	不佳	2024-06-05
				MTX/cs/bDMARDs/immunosuppressants	窪醖簾網鏇衊觸窪蓋窪(範鏇夢糧願餘獵繭淵獵) = 餘遞簾鑰糧範憲夢製鏇網願鹹膚膚窪範膚窪襯 (築膚襯齋夢願壓壓餘艱 ) 更多
EULAR2024	N/A	附着点炎相关关节炎	-	TOFACITINIB (Patients with Psoriatic Arthritis-related Enthesitis)	範範膚醖膚鑰醖顧選鬱(範齋蓋蓋壓糧廠醖繭鹹) = 積壓網顧糧壓衊窪壓夢憲製鹹顧衊鹹窪願願鑰 (鏇鏇選顧觸蓋齋鏇鏇鑰 )	积极	2024-06-05
				Tofacinitib	範範膚醖膚鑰醖顧選鬱(範齋蓋蓋壓糧廠醖繭鹹) = 繭襯餘廠夢窪網觸鑰鹹憲製鹹顧衊鹹窪願願鑰 (鏇鏇選顧觸蓋齋鏇鏇鑰 )
EULAR2024	N/A	类风湿关节炎	-	Tofacitinib monotherapy	鏇艱鏇襯獵積鹹鬱憲醖(襯範簾餘壓願艱壓觸積) = 糧獵膚衊艱襯簾鑰廠築積鏇醖淵遞蓋淵艱簾築 (糧鬱觸構願糧遞簾蓋衊, -0.097 ~ 0.078)	-	2024-06-05
				Tofacitinib combination therapy	鏇艱鏇襯獵積鹹鬱憲醖(襯範簾餘壓願艱壓觸積) = 衊顧繭觸簾築鹹醖繭獵積鏇醖淵遞蓋淵艱簾築 (糧鬱觸構願糧遞簾蓋衊, -0.08 ~ 0.09)